• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by XBiotech Inc.

    2/10/23 12:21:09 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XBIT alert in real time by email
    SC 13G 1 sc13g_021023.htm FORM SC 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

     

    XBIOTECH INC.
    (Name of Issuer)
     
    Common Shares, no par value
    (Title of Class of Securities)
     
    98400H102
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [_] Rule 13d-1(b)

     

    [ ] Rule 13d-1(c)

     

    [x] Rule 13d-1(d)

     

    1The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

     

     

     

    SCHEDULE 13G

     

    CUSIP No. 98400H102  

     

    1 Names of Reporting Persons    
      W. Thorpe McKenzie      
    2 Check the appropriate box if a member of a Group (see instructions)      
     

    (a)  [ ]

    (b)  [ ]

           
    3 Sec Use Only        
                 
    4 Citizenship or Place of Organization          
      USA            

    Number of Shares Beneficially Owned by Each Reporting Person With:

     

    5 Sole Voting Power            
        2,929,971 (1)              
      6 Shared Voting Power                  
        106,288(3)                    
      7 Sole Dispositive Power                        
        2,929,971(1)                          
      8 Shared Dispositive Power                              
        106,288(3)                                
                                     
    9 Aggregate Amount Beneficially Owned by Each Reporting Person                                
      3,036,259(1)(2)                                  
                                       
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)                                  
      [ ]                                    
    11 Percent of class represented by amount in row (9)                                    
      9.87%(4)                                    
    12 Type of Reporting Person (See Instructions)                                    
      IN                                    
                                               
                                                 

     

    Page 2 of 7

     

     

      (1) These figures include shares of common stock underlying stock options held by the Reporting Person, including options that are immediately exercisable within 60 days of December 31, 2022.

     

      (2) Includes 66,748 shares held by the McKenzie Foundation, 31,864 shares held by Mr. McKenzie’s spouse and 7,676 shares held in a Trust for Mr. McKenzie’s stepchildren.

     

      (3) The Reporting Person’s spouse owns, controls and holds sole dispositive power to 106,288 shares for which the Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The Reporting Person’s Foundation owns, controls and holds sole dispositive power to 66,748 shares for which the Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The Reporting Person’s stepchildren owns, controls and holds sole dispositive power to 7,676 shares for which the Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

     

      (4) The percentage is calculated based upon 30,439,275 shares outstanding as of December 31, 2022.

     

     

     

     

     

    Page 3 of 7

     

     

    Item 1.

     

      (a) Name of Issuer:

     

    XBiotech Inc.

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    5217 Winnebago Ln, Austin, TX 78744

     

    Item 2.

     

      (a) Name of Person Filing:

     

    W. Thorpe McKenzie

     

      (b) Address of Principal Business Office or, if None, Residence:

     

    832 Georgia Avenue, Suite 1100

    Chattanooga, TN 37402

     

      (c) Citizenship:

     

    USA

     

      (d) Title and Class of Securities:

     

    Common Shares, no par value

     

      (e) CUSIP No.:

     

    98400H102

     

      Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable

     

      Item 4. Ownership

     

    As of December 31, 2022

     

      (a) Amount Beneficially Owned:

     

    3,036,259(1)(2) shares

     

      (b) Percent of Class:

     

    9.87%(4)

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote:

     

    2,929,971(1) shares

    Page 4 of 7

     

     

      (ii) Shared power to vote or to direct the vote:

     

    106,288(3)

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    2,929,971 (1) shares

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    106,288 (3)

     

      (1) These figures include shares of common stock underlying stock options held by the Reporting Person, including options that are immediately exercisable within 60 days of December 31, 2022.

     

      (2) Includes 66,748 shares held by the McKenzie Foundation, 31,864 shares held by Mr. McKenzie’s spouse and 7,676 shares held in a Trust for Mr. McKenzie’s stepchildren.

     

      (3) The Reporting Person’s spouse owns, controls and holds sole dispositive power to 106,288 shares for which the Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The Reporting Person’s Foundation owns, controls and holds sole dispositive power to 66,748 shares for which the Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. The Reporting Person’s stepchildren owns, controls and holds sole dispositive power to 7,676 shares for which the Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

     

      (4) The percentage is calculated based upon 30,439,275 shares outstanding as of December 31, 2022.

     

      Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable

     

      Item 6. Ownership of more than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

      Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Not Applicable

     

      Item 8. Identification and classification of members of the group.

     

    Not Applicable

     

    Page 5 of 7

     

     

      Item 9. Notice of Dissolution of Group.

     

    Not Applicable

     

      Item 10. Certifications.

     

    Not Applicable

     

     

     

    Page 6 of 7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  February 10, 2023

     

    /s/ W. Thorpe McKenzie

     

    W. Thorpe McKenzie

     

     

     

     

    Page 7 of 7

     

     

     

    Get the next $XBIT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XBIT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XBIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:36:43 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:01:48 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:01:06 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XBiotech Pauses Rheumatology program

      AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid Arthritis. The Phase II study failed to meet its primary endpoint amid substantial irregularities that make unequivocal interpretation of the findings difficult. XBiotech was planning launch of additional studies in arthritis as well as other areas of rheumatology, including ankylosing spondylitis, which are now on hold while recent findings are evaluated. About 230 subjects with modera

      12/23/24 9:00:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

      AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less then ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the Company believes it might po

      6/18/24 11:35:14 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

      AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate we

      1/4/24 9:00:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Financials

    Live finance-specific insights

    See more

    $XBIT
    SEC Filings

    See more
    • XBiotech Announces Payment of Dividend to Holders of Common Stock

      AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. In the past 18 months, XBiotech's balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human™ antibody drug

      7/30/21 11:03:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Announces Dividend to Holders of Common Stock

      AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ:XBIT) ("XBiotech") Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021. "XBiotech's proven ability to develop highly valued drug candidates, revenue from contract operations, judicious deployment of operating capital, absence of debt, and very significant emerging opportunities in our pipeline, has created the balance sheet flexibility that enables us to provide shareholder

      7/6/21 4:30:00 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by XBiotech Inc.

      10-K/A - XBiotech Inc. (0001626878) (Filer)

      4/29/25 3:59:49 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - XBiotech Inc. (0001626878) (Filer)

      4/7/25 4:50:51 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Inc. filed SEC Form 8-K: Leadership Update

      8-K - XBiotech Inc. (0001626878) (Filer)

      3/31/25 6:43:56 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Simard John

      4 - XBiotech Inc. (0001626878) (Issuer)

      3/19/25 3:03:42 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Simard John

      4 - XBiotech Inc. (0001626878) (Issuer)

      2/4/25 4:53:27 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mckenzie W Thorpe

      4 - XBiotech Inc. (0001626878) (Issuer)

      6/21/24 2:16:44 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care